TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.51E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.98E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 7.94E+3nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.58E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.16E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 3.98E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <5.01E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <5.01E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <5.01E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 5.01E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <5.01E+4nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 6.31E+4nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 1.58E+5nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <2.51E+5nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <2.51E+5nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <2.51E+5nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2A(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: <2.51E+5nMAssay Description:Inhibition of human recombinant NR1/NR2A receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Glaxosmithkline Medicines Research Centre
Curated by ChEMBL
Affinity DataIC50: 2.51E+5nMAssay Description:Inhibition of human recombinant NR1/NR2B receptor expressed in U2OS assessed as change in intracellular calcium level by FLIPR assayMore data for this Ligand-Target Pair